Paul Hastings Represents BioMarin in $911 Million Public Offering of Common Stock
January 29, 2015
San Francisco, CA- Paul Hastings LLP, a leading global law firm, represented BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a pharmaceutical company that develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, in connection with its underwritten public offering of 9,775,000 shares of common stock. BioMarin estimated the offering would raise gross proceeds of $911.5 million before costs.
BofA Merrill Lynch acted as representative of the underwriters, J.P. Morgan and Morgan Stanley acted as joint book-running managers for the offering, and Barclays and Deutsche Bank Securities Inc. acted as co-managers for the offering.
Paul Hastings has also advised BioMarin in a $119.3 offering in March 2014 and a $750 million offering in October 2013.
Paul Hastings is a leading global law firm with a strong presence throughout Asia, Europe, Latin America, and the United States. Through a collaborative approach, entrepreneurial spirit, and commitment to client service, the professionals of Paul Hastings deliver innovative solutions to many of the world’s top financial institutions and Fortune 500 companies.